Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUnicorn Asset Management Regulatory News (UAV)

Share Price Information for Unicorn Asset Management (UAV)

Share Price is delayed by 15 minutes
Get Live Data
70.00    0.00 (0.00%)
Bid:
67.00
Ask:
73.00
Spread: 6.00 (8.955%)
Market Cap: £180.27m
UAV Live PriceLast checked at - London Stock Exchange

Intraday Unicorn Asset Management Share Chart

Interim Management Statement

30 Jan 2023 11:24

RNS Number : 2740O
Unicorn AIM VCT PLC
30 January 2023
 

Unicorn AIM VCT plc ("the Company")

Interim Management Statement

For the period from 1 October 2022 to 31 December 2022

 

Introduction

 

This voluntary Interim Management Statement ("IMS") covers the three-month period ended 31 December 2022, together with relevant information up to the date of publication. 

 

Investment Objective

 

The Company's objective is to provide Shareholders with an attractive return from a diversified portfolio of investments, predominantly in the shares of AIM quoted companies, by maintaining a steady flow of dividend distributions to Shareholders from the income as well as capital gains generated by the portfolio.

 

It is also the objective that the Company should continue to qualify as a Venture Capital Trust ("VCT"), so that Shareholders benefit from the taxation advantages that this brings. To achieve this, at least 80% of the Company's total assets are to be invested in qualifying investments of which 70% by VCT value (30% in respect of investments made before 6 April 2018 from funds raised before 6 April 2011) must be in ordinary shares, which carry no preferential rights (save as permitted under VCT rules) to dividends or return of capital and no rights to redemption.

 

Performance

 

The performance of the portfolio was flat in the three-month period under review, as the Company's net asset value per Share increased by just 0.1% from 134.8p per Share to 135.0p per Share (unaudited).

 

In comparison, the FTSE AIM All-Share Index posted a total return of +3.6% during the same period.

 

The outperformance of the FTSE AIM All-Share Index in the first quarter of the Company's financial year was partly due to a recovery in the valuation of AIM-listed businesses that operate within the financial services sector, to which the investment portfolio has relatively low exposure. In addition, the share price of MaxCyte, a life sciences business in which the Company holds a meaningful stake, remained under pressure during the period, despite having released very positive news.

 

We are confident that the modest relative underperformance recorded during the first quarter can be reversed during the remainder of the Company's current financial year.

 

Outlook

 

Despite recent economic headwinds, the operational performance of many of our AIM-listed companies has been reassuringly resilient. A large proportion of our investee companies are well established, profitable and cash generative businesses, which sell highly specialised products and services for which there is typically continuing, strong demand. While the immediate outlook for less mature companies remains challenging, it is reasonable to anticipate positive returns from these businesses once market conditions become more favourable.

 

Against this backdrop, our approach to backing new companies remains highly selective.

 

We remain confident that we will continue to find exciting investment opportunities that, over time, are capable of delivering a combination of tax-free dividend income and capital growth. We are also confident that, once economic and political stability returns, the FTSE AIM All-Share Index and the Company's carefully selected portfolio of investments will recover in value.

 

In the meantime, we continue to nurture the promising portfolio of existing investments, and are confident that most of our investee companies can withstand an extended period of economic hardship, and, in many cases, have the potential to become valuable businesses within the next 5-10 years.

 

As at 31 December 2022, an estimated 99.0% of total assets (by VCT value and excluding new capital) were invested in VCT qualifying companies. This figure is significantly above the 80% threshold that the Company is required, by HMRC, to maintain.

Material Transactions

Capital was committed to two investments in the three-month period ended 31 December 2022. These investments were:-

· A new investment of £2.0 million in Oxford Biodynamics PLC in October 2022 and;

 

· A follow-on investment of £0.1 million in SulNOx Group PLC, which completed in January 2023

Top Ten VCT Qualifying Holdings as at 31 December 2022

Stock

% of Net Assets

Hasgrove

9.1

Tracsis

7.2

Abcam

6.8

MaxCyte

4.8

Anpario

4.1

Avingtrans

3.7

Surface Transforms

3.1

 Keywords Studios

3.0

 Tristel

2.8

 Cohort plc

2.7

 

 

Total

47.3

 

Share Buy-Backs

 

No share buybacks were undertaken in the period under review.

 

Offer for Subscription

 

A new Offer for Subscription to raise up to £10 million, with an over-allotment facility to raise up to a further £5 million was launched on 24 January 2023. Details of this offer are set out in a Prospectus issued by the Company on 24 January 2023, which is available online at https://www.unicornaimvct.co.uk. The Offer will open for applications at 9.00 a.m. on 6 February 2023 and will close for applications at 5.30 p.m. on 30 March 2023 (or, if earlier, as soon as the Offer is fully subscribed or otherwise at the board's discretion). Applications in relation to this Offer can only be made for the 2022/2023 tax year.

 

Dividends

As advised in the Annual Report, the Board has recommended a final dividend of 3.5 pence per share in respect of the Company's financial year ended 30 September 2022. Subject to receiving Shareholder approval at the Annual General Meeting on 7 February 2023, this dividend will be paid on 14 February 2023 to eligible Shareholders who were on the register on 6 January 2023.

Material Events

There were no material events during the period from 1 October 2022 to 31 December 2022.

 

Chris Hutchinson

Unicorn Asset Management

Investment Director

 

30 January 2023

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRZZGFMMGGGFZM
Date   Source Headline
14th Feb 202410:23 amRNSIssue of Equity
8th Feb 20243:47 pmRNSOffer for Subscription - Update
7th Feb 20245:43 pmRNSResult of AGM
5th Feb 20243:37 pmRNSNet Asset Value(s)
1st Feb 20242:53 pmRNSInterim Management Statement
26th Jan 202411:47 amRNSOffer for Subscription and Issue of Prospectus
11th Jan 20247:00 amRNSDividend Declaration
9th Jan 202410:39 amRNSNet Asset Value(s)
20th Dec 20233:06 pmRNSDirector Declaration
8th Dec 20237:00 amRNSFinal Results
6th Dec 20233:47 pmRNSNet Asset Value(s)
28th Nov 202310:00 amRNSIntention to launch an Offer
6th Nov 20234:48 pmRNSNet Asset Value(s)
17th Oct 20235:04 pmRNSNet Asset Value(s)
2nd Oct 20239:19 amRNSTotal Voting Rights
25th Sep 20239:18 amRNSTransaction in Own Shares
7th Sep 202311:40 amRNSNet Asset Value(s)
1st Sep 202311:39 amRNSTotal Voting Rights
25th Aug 20239:16 amRNSTransaction in Own Shares
14th Aug 202312:42 pmRNSDirector/PDMR Shareholding
11th Aug 20231:47 pmRNSIssue of Equity under Dividend Reinvestment Scheme
4th Aug 202310:57 amRNSNet Asset Value(s)
1st Aug 202310:19 amRNSTotal Voting Rights
19th Jul 20237:00 amRNSTransaction in Own Shares
7th Jul 20239:12 amRNSNet Asset Value(s)
3rd Jul 202312:23 pmRNSTotal Voting Rights
9th Jun 20234:11 pmRNSTransaction in Own Shares
6th Jun 20232:18 pmRNSHolding(s) in Company
5th Jun 20234:43 pmRNSNet Asset Value(s)
31st May 20237:00 amRNSHalf-year Report
5th May 20239:20 amRNSNet Asset Value(s)
6th Apr 202310:53 amRNSNet Asset Value(s)
3rd Apr 202310:25 amRNSTotal Voting Rights
10th Mar 20234:32 pmRNSTransaction in Own Shares
3rd Mar 20235:36 pmRNSNet Asset Value(s)
1st Mar 20239:52 amRNSTotal Voting Rights
22nd Feb 20234:04 pmRNSDirector/PDMR Shareholding
22nd Feb 20239:14 amRNSIssue of Equity
21st Feb 202311:43 amRNSNet Asset Value(s)
14th Feb 202312:42 pmRNSIssue of Equity
13th Feb 20234:53 pmRNSTransaction in Own Shares
7th Feb 20236:14 pmRNSResult of AGM
6th Feb 20235:30 pmRNSOffer for Subscription Update
6th Feb 202312:02 pmRNSOffer for Subscription – Update
6th Feb 20237:00 amRNSNet Asset Value(s)
1st Feb 202310:34 amRNSTotal Voting Rights
30th Jan 202311:24 amRNSInterim Management Statement
24th Jan 202312:09 pmRNSOffer for Subscription and Issue of Prospectus
16th Jan 20239:51 amRNSTransaction in Own Shares
6th Jan 20233:06 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.